Table SI. Pubmed search strategy.
((((((Camrelizumab) OR (Sintilimab)) OR (Tislelizumab)) OR (Toripalimab)) OR (Envafolimab)) OR ((anti-CTLA4 antibody) OR (anti-CTLA4 antibodies)) OR (Immune Checkpoint Inhibitors)) OR (Checkpoint Inhibitors, Immune)) OR (Immune Checkpoint Inhibitor)) OR (Checkpoint Inhibitor, Immune)) OR (Immune Checkpoint Blockers)) OR (Checkpoint Blockers, Immune)) OR (Immune Checkpoint Blockade)) OR (Checkpoint Blockade, Immune)) OR (Immune Checkpoint Inhibition)) OR (Checkpoint Inhibition, Immune)) OR (PD-L1 Inhibitors)) OR (PD L1 Inhibitors)) OR (PD-L1 Inhibitor)) OR (PD L1 Inhibitor)) OR (Programmed Death-Ligand 1 Inhibitors)) OR (Programmed Death Ligand 1 Inhibitors)) OR (PD-1-PD-L1 Blockade)) OR (Blockade, PD-1-PD-L1)) OR (PD 1 PD L1 Blockade)) OR (CTLA-4 Inhibitors)) OR (CTLA 4 Inhibitors)) OR (CTLA-4 Inhibitor)) OR (CTLA 4 Inhibitor)) OR (Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors)) OR (Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors)) OR (Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor)) OR (Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor)) OR (PD-1 Inhibitors)) OR (PD-1 Inhibitor)) OR (PD 1 Inhibitors)) OR (Inhibitor, PD-1)) OR (PD 1 Inhibitor)) OR (Programmed Cell Death Protein 1 Inhibitor)) OR (Programmed Cell Death Protein 1 Inhibitors)) OR (pembrolizumab)) OR (nivolumab)) OR (atezolizumab)) OR (ipilimumab)) OR (avelumab)) OR (tremelimumab)) OR (durvalumab)) OR (cemiplimab)) OR (anti-PD-1 antibodies)) OR (anti-PD-1 antibody)) OR (anti-PD-L1 antibody)) OR (anti-PD-L1 antibodies)) OR (Immune Checkpoint Inhibitors[MeSH Terms]))) AND (("Glasgow Prognostic Score") OR ("Modified Glasgow Prognostic Score"))

Table SII. Quality assessment of the included studies.

Study	(Refs.)	Selection				Comparability	Exposure			Scores
		Adequate definition of cases	Representat-iveness of the cases	Selection of controls	Definition of controls	Control for important factor	Ascertain-ment of exposure	Same method of ascertainment for cases and controls	Non-response rate	
Tanaka *et al* 2023	(56)	★	★	-	★	★	★	★	-	7
Takegawa *et al* 2023	(63)	★	-	-	★	★★	★	★	-	7
Madeddu *et al* 2023	(42)	★	★	★	★	★★	★	★	★	8
Kasajima *et al* 2023	(39)	★	★	-	★	★	★	★	-	7
Wasamoto *et al* 2022	(59)	★	★	★	★	★	★	★	★	8
Diker *et al* 2022	(24)	★	★	★	★	★★	★	★	-	8
Zaitsu *et al* 2021	(62)	★	★	-	★	★	★	★	★	7
Takamori *et al* 2021	(55)	★	★	★	★	★★	★	★	-	8
Ogura *et al* 2021	(52)	-	★	-	★	★	★	★	-	6
Kang *et al* 2021	(37)	★	★	-	★	★	★	★	★	7
Imai *et al* 2021	(36)	★	★	★	★	★	★	★	★	8
Freitas *et al* 2021	(26)	★	★	★	★	★	★	★	-	7
Araki *et al* 2021	(31)	★	★	-	★	★★	★	★	-	7
Ali *et al* 2021	(30)	★	★	★	★	★	★	★	★	8
Matsubara *et al* 2020	(43)	★	★	★	★	★	★	-	-	6
Kasahara *et al* 2019	(38)	★	★	★	★	★	★	★	-	7
Kawakami *et al* 2023	(40)	★	-	★	★	★	★	★	★	7
Sakai *et al* 2022	(53)	★	-	★	★	★★	★	★	-	7
Tokuyama *et al* 2021	(57)	★	★	-	★	★	★	★	-	6
Namikawa *et al* 2020	(49)	★	★	★	-	★	★	★	-	6
Kurosaki *et al* 2020	(41)	★	★	★	★	★	★	★	-	7
Matsuo *et al* 2022	(45)	★	★	★	★	★★	★	★	-	8
Minohara *et al* 2021	(47)	★	★	★	★	★	★	★	-	7
Chikuie *et al* 2021	(34)	★	★	★	★	★	★	★	-	7
Ueki *et al* 2020	(58)	★	★	★	★	★	★	★	-	7
Matsuki *et al* 2020	(44)	★	★	★	★	★	★	★	-	7
Yamamoto *et al* 2021	(60)	★	★	★	★	★★	★	★	-	8
Brown *et al* 2021 (UC)	(33)	★	★	★	★	★	★	★	★	8
Fujiwara *et al* 2021	(35)	★	★	★	★	★	★	★	-	7
Brown *et al* 2021 (RCC)	(32)	★	★	★	★	★	★	★	★	8
Yamamoto *et al* 2020	(25)	★	★	★	★	★	★	★	-	7

Noguchi *et al* 2020	(51)	★	★	-	★	★	★	★	-	6
Minichsdorfer *et al* 2022	(46)	★	★	★	★	★	★	★	-	7
Tada *et al* 2023	(54)	★	★	-	★	★	★	★	★	7
Yang *et al* 2022	(61)	★	★	-	★	★★	★	★	★	8
Mortensen *et al* 2023	(48)	★	★	★	★	★	★	★	-	7
Tanaka *et al* 2023	(64)	★	★	-	★	★	★	★	-	6
Niwa *et al* 2020	(50)	★	-	★	★	★	★	★	-	6

UC, urothelial carcinoma; RCC, renal cell carcinoma.